Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...

J&J's high expectations for Rybrevant are driven mainly by its August approval with Lazcluze, which outperformed Tagrisso in ...

The challenge persists, but, with a renewed focus from regulatory bodies and trial sponsors alike on improving enrolment ...

Employees at Achilles Therapeutics are bracing themselves for job losses after the UK biotech announced that it is dropping ...

Astellas is ready to launch its first digital health offering in the US, a toolkit dedicated to providing at-home monitoring ...

Biogen says it is the first drugmaker in the US to get FDA approval for a biosimilar of Roche’s $3 billion blockbuster product Actemra. The intravenous biosimilar of IL-6 inhibitor Actemra ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category for ...

Johnson & Johnson has submitted its first marketing application for nipocalimab, seeking approval for the FcRn blocker in generalised myasthenia gravis (gMG), where it would compete with rivals in ...

The FDA has declined to approve Vanda Pharma's tradipitant for delayed gastric emptying (gastroparesis), prompting a furious ...

Global events can pose significant challenges to the supply of APIs, and thus the continuity of drug supply. Any disruption ...

Elon Musk's Neuralink has been awarded breakthrough status from the FDA for an implantable chip – dubbed Blindsight – that ...